Abstract
Stem cell therapy currently seems to be pushing back limits to science. However, on the clinician's perspective, many results must be relativized, since efficiency and relevancy criterion are far away from practical reality. Therefore, we took an interest in the potential use of stem cell therapy in patients with peripheral artery disease. Through a retrospective clinical study, we identified a group of patients in which cell therapy could potentially be of interest, in terms of public health and cost. We demonstrated that this group corresponds to diabetic patients on Rutherford's stage 5. For this group of patients, we pave the way for a stem cell therapy clinical trial, associated with conventional care, with wound healing time and reintervention rate as endpoints.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
